Abstract
Targeted delivery of cytotoxic agents to tumours is believed to improve both their anti-tumour efficacy and their safety. Antibodies specific for tumour-associated antigens have been used to deliver cytotoxic agents to tumour cells. Calicheamicin is a potent cytotoxic agent that causes double-strand DNA breaks, resulting in cell death. When conjugated to monoclonal antibodies specific for tumour-associated antigens, calicheamicin exerts strong antigen-specific anti-tumour effects against human tumour xenografts in preclinical models. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin, exemplified by gemtuzumab ozogamicin (Mylotarg), is a clinically validated therapeutic strategy for the treatment of human cancer.
MeSH terms
-
Aminoglycosides / chemistry
-
Aminoglycosides / pharmacology
-
Aminoglycosides / therapeutic use*
-
Animals
-
Antibodies, Monoclonal / chemistry
-
Antibodies, Monoclonal / pharmacology*
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antigens, CD / immunology
-
Antigens, Differentiation, B-Lymphocyte / immunology
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Cell Adhesion Molecules*
-
Clinical Trials as Topic
-
Enediynes
-
Gemtuzumab
-
Humans
-
Immunoconjugates / chemistry
-
Immunoconjugates / pharmacology
-
Immunoconjugates / therapeutic use*
-
Inotuzumab Ozogamicin
-
Lectins / immunology
-
Leukemia, Myeloid, Acute / drug therapy
-
Lymphoma, B-Cell / drug therapy
-
Sialic Acid Binding Ig-like Lectin 2
Substances
-
Aminoglycosides
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antigens, CD
-
Antigens, Differentiation, B-Lymphocyte
-
Antineoplastic Agents
-
CD22 protein, human
-
Cell Adhesion Molecules
-
Enediynes
-
Immunoconjugates
-
Lectins
-
Sialic Acid Binding Ig-like Lectin 2
-
calicheamicin gamma(1)I
-
Gemtuzumab
-
Inotuzumab Ozogamicin